About Thyssen Biopharmaceuticals
Thyssen Biopharmaceuticals is a company based in Pohang-si (South Korea) founded in 2021. Thyssen Biopharmaceuticals has raised $1.59 million across 1 funding round from investors including Envisioning Partners, Stonebridge Ventures and FuturePlay. Thyssen Biopharmaceuticals offers products and services including Cell-Grown Meat. Thyssen Biopharmaceuticals operates in a competitive market with competitors including Simple Planet, HN Novatech, Innohas, DaNAgreen and SEAWITH, among others.
- Headquarter Pohang-si, South Korea
- SectorsConsumer
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website tissenbiofarm.com
- Social LinkedIn X Instagram YouTube
- Total Equity Funding$1.59M (USD)
in 1 rounds
- Latest Funding Round$1.59M (USD), Seed
Sep 2022
- InvestorsEnvisioning Partners
& 3 more
Products & Services of Thyssen Biopharmaceuticals
Thyssen Biopharmaceuticals offers a comprehensive portfolio of products and services, including Cell-Grown Meat.
Sustainable meat produced by cultivating animal cells without farming.
Apps and channels of Thyssen Biopharmaceuticals
its YouTube channel TissenBioFarm has 215 subscribers and 5 videos.
Videos from Thyssen Biopharmaceuticals
The most watched videos on Thyssen Biopharmaceuticals's YouTube channel, TissenBioFarm (215 subscribers). Click a video to play it here.
More on TissenBioFarm.
Funding Insights of Thyssen Biopharmaceuticals
Thyssen Biopharmaceuticals has successfully raised a total of $1.59M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.59 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.59M
- Total Rounds 1
- Last Round Seed β $1.59M
- First Round $1.59M
(Sep 2022)
- Investors Count 4
All 1 funding rounds of Thyssen Biopharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2022 | $1.59M | Seed | β | Envisioning Partners |
4 investors in total: 4 institutional.
Investors in Thyssen Biopharmaceuticals
Thyssen Biopharmaceuticals has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Envisioning Partners, Stonebridge Ventures and FuturePlay.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
No specific activity is described for this entity. | – | envisioning.partners | - | |
Venture capital investments in technology and AI sectors are provided. | – | stonebridgeventures.vc | Seoul, South Korea | |
FuturePlay is engaged in startup investment and acceleration. | – | futureplay.co | Seoul, South Korea | |
Investment in technology-based startups is managed by Mirae Holdings. | 2014 | miraeholding.com | Daejeon, South Korea |
Investor details for Thyssen Biopharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Thyssen Biopharmaceuticals
1 people are tracked at Thyssen Biopharmaceuticals (1 in leadership).
| Name | Role | Group |
|---|---|---|
Wonil Han | CEO | Leadership |
Complete people profiles for Thyssen Biopharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Thyssen Biopharmaceuticals
2 dated milestones of Thyssen Biopharmaceuticals across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Thyssen Biopharmaceuticals is founded.
- Funding First funding round of $1.6M.
Competitors of Thyssen Biopharmaceuticals
Thyssen Biopharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Simple Planet, HN Novatech, Innohas, DaNAgreen and SEAWITH, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| simpleplanet.io | 2021 | Seoul, South Korea | $7.5M | – | Provider of plant-based cultivated meat | |
| hnnt.co.kr | 2021 | Anyang, South Korea | $4M | – | Platform offering alternative meat products | |
| innohas.com | 2021 | Seoul, South Korea | – | – | Plant-based meat substitute novel food products are developed by Innohas. | |
| danagreenbio.com | 2013 | Seoul, South Korea | $7M | – | Provider of scaffolds to culture cells in 3D | |
| seawith.net | 2019 | Daegu, South Korea | – | – | Cultured meat products are developed from seaweed using lab-based methods. |
Detailed competitors of Thyssen Biopharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Thyssen Biopharmaceuticals
Complete news archive for Thyssen Biopharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Thyssen Biopharmaceuticals
10 companies that operate in the same segment as Thyssen Biopharmaceuticals (Food & Beverage Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Online platform food ordering and delivery service | 2008 | Gurugram, Haryana, India | USD 1.69 B | USD 5.79 B | 7,780 | |
Food and grocery deliveries are facilitated through an app-based platform. | 2013 | San Francisco, California, United States | USD 2.47 B | USD 10.72 B | 23,700 | |
Food and grocery items are ordered via an online network. | 2014 | Bengaluru, Karnataka, India | USD 3.54 B | USD 2.46 B | 4,490 | |
Online marketplace offering multi-category grocery products | 2015 | Barcelona, Catalonia, Spain | USD 1.16 B | – | – | |
Food and market delivery services are provided by iFood. | 2011 | Sao Paulo, Brazil | USD 590.8 M | – | – | |
Platform for discovering and sharing local businesses | 2004 | San Francisco, California, United States | USD 56 M | USD 1.46 B | 5,120 | |
Restaurant operations are managed via a cloud-based platform. | 2011 | Boston, Massachusetts, United States | USD 1.15 B | USD 6.15 B | 5,700 | |
Online platform offering discovery of local deals, experiences, and rewards | 2015 | Gurugram, Haryana, India | USD 105.82 M | USD 37.82 M | 414 | |
Wolt is operated as a delivery platform for food and groceries. | 2014 | Helsinki, Finland | USD 827.96 M | – | – | |
Food delivery services are offered in major Indian cities. | 2012 | Mumbai, Maharashtra, India | USD 97.72 M | USD 39.01 M | 3,150 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Thyssen Biopharmaceuticals
Thyssen Biopharmaceuticals was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Thyssen Biopharmaceuticals is headquartered in Pohang-si, South Korea. It is registered at Pohang-si, North Gyeongsang Province, South Korea.
Wonil Han is the current CEO of Thyssen Biopharmaceuticals.
Thyssen Biopharmaceuticals is a funded company, having raised a total of $1.59M across 1 funding round to date. The company's 1st funding round was a Seed of $1.59M, raised on Sep 2022.
Thyssen Biopharmaceuticals was established in 2021 as a biopharmaceutical entity. An online platform is maintained to distribute lab-grown meat substitutes produced through tissue engineering. Cultivated meat is manufactured in kilogram quantities, featuring realistic texture and marbling. Artificial organs for medical applications are also developed using similar technologies. Operations center on innovations in food alternatives and regenerative medicine, with details on geographic presence unavailable.
Thyssen Biopharmaceuticals's top competitors include Simple Planet, DaNAgreen and HN Novatech.
Thyssen Biopharmaceuticals offers Cell-Grown Meat.
Thyssen Biopharmaceuticals has 4 investors. Key investors include Envisioning Partners, Stonebridge Ventures, FuturePlay, and Mirae Holdings.